Ignite Creation Date:
2025-12-24 @ 5:24 PM
Ignite Modification Date:
2025-12-28 @ 8:13 PM
Study NCT ID:
NCT01168050
Status:
UNKNOWN
Last Update Posted:
2011-02-08
First Post:
2010-07-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-07
Start Date Type:
None
Primary Completion Date:
2013-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2013-12
Completion Date Type:
ESTIMATED
First Submit Date:
2010-07-21
First Submit QC Date:
None
Study First Post Date:
2010-07-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2011-02-07
Last Update Post Date:
2011-02-08
Last Update Post Date Type:
ESTIMATED